Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials.

Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials.

The VRC01 Antibody Mediated Prevention (AMP) efficacy trials conducted between 2016 and 2020 showed for the first time that passively administered broadly neutralizing antibodies (bnAbs) could prevent HIV-1 acquisition against bnAb-sensitive viruses. HIV-1 viruses isolated from AMP participants who...

Full description

Bibliographic Details
Main Authors:	Nonhlanhla N Mkhize, Anna E J Yssel, Haajira Kaldine, Rebecca T van Dorsten, Amanda S Woodward Davis, Nicolas Beaume, David Matten, Bronwen Lambson, Tandile Modise, Prudence Kgagudi, Talita York, Dylan H Westfall, Elena E Giorgi, Bette Korber, Colin Anthony, Rutendo E Mapengo, Valerie Bekker, Elizabeth Domin, Amanda Eaton, Wenjie Deng, Allan DeCamp, Yunda Huang, Peter B Gilbert, Asanda Gwashu-Nyangiwe, Ruwayhida Thebus, Nonkululeko Ndabambi, Dieter Mielke, Nyaradzo Mgodi, Shelly Karuna, Srilatha Edupuganti, Michael S Seaman, Lawrence Corey, Myron S Cohen, John Hural, M Juliana McElrath, James I Mullins, David Montefiori, Penny L Moore, Carolyn Williamson, Lynn Morris
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2023-06-01
Series:	PLoS Pathogens
Online Access:	https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1011469&type=printable

Similar Items

Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
by: Yunda Huang, et al.
Published: (2023-11-01)

Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants
by: Yunda Huang, et al.
Published: (2022-01-01)

Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials
by: Yunda Huang, et al.
Published: (2021-02-01)

Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features.
by: Craig A Magaret, et al.
Published: (2019-04-01)

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisitionResearch in context
by: Kelly E. Seaton, et al.
Published: (2023-07-01)

FINAD + VRC = Controllers Instituut
by: G. H. Koolman
Published: (1995-05-01)

Sequence and functional characterization of a public HIV-specific antibody clonotype
by: Amyn A. Murji, et al.
Published: (2022-01-01)

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages
by: Jinal N. Bhiman, et al.
Published: (2023-01-01)

Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination
by: Boitumelo M. Motsoeneng, et al.
Published: (2023-08-01)

Adjuvants influence the maturation of VRC01-like antibodies during immunization
by: Maria L. Knudsen, et al.
Published: (2022-11-01)

Partial germline reversions can increase VRC07 potency and breadth
by: Rudicell RS, et al.
Published: (2012-09-01)

P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)
by: Nabel GJ, et al.
Published: (2009-10-01)

Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms
by: Thandeka Moyo-Gwete, et al.
Published: (2022-10-01)

Engineered gp120 immunogens that elicit VRC01-like antibodies by vaccination
by: Mata-Fink, Jordi, et al.
Published: (2013)

Mendeteksi dan membetulkan kesalahan data digital menggunakan metode VRC dan LRC
by: , RASYID, Rum Mohamad Andri Kristiyanto, et al.
Published: (2001)

Selection of peptide mimics of HIV-1 epitope recognized by neutralizing antibody VRC01.
by: Anton N Chikaev, et al.
Published: (2015-01-01)

Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization
by: K. Rachael Parks, et al.
Published: (2019-12-01)

Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011).
by: Mary E Enama, et al.
Published: (2014-01-01)

Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials
by: Yunda Huang, et al.
Published: (2018-09-01)

Endemic mycoses in South Africa, 2010-2020: A decade-long description of laboratory-diagnosed cases and prospects for the future.
by: Rutendo E Mapengo, et al.
Published: (2022-09-01)

Endemic mycoses in South Africa, 2010–2020: A decade-long description of laboratory-diagnosed cases and prospects for the future
by: Rutendo E. Mapengo, et al.
Published: (2022-09-01)

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
by: Celia C LaBranche, et al.
Published: (2018-11-01)

Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
by: Celia C LaBranche, et al.
Published: (2019-03-01)

Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies
by: Emilie Seydoux, et al.
Published: (2021-05-01)

Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01
by: Lynch RM, et al.
Published: (2012-09-01)

Modeling HIV-1 Within-Host Dynamics After Passive Infusion of the Broadly Neutralizing Antibody VRC01
by: E. Fabian Cardozo-Ojeda, et al.
Published: (2021-08-01)

Delayed vaginal SHIV infection in VRC01 and anti-α4β7 treated rhesus macaques.
by: Giulia Calenda, et al.
Published: (2019-05-01)

Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies.
by: Cathrine Scheepers, et al.
Published: (2022-09-01)

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
by: Labranche, CC, et al.
Published: (2018)

Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain
by: Young D. Kwon, et al.
Published: (2023-12-01)

Pre-existing resistance in the latent reservoir can compromise VRC01 therapy during chronic HIV-1 infection.
by: Ananya Saha, et al.
Published: (2020-11-01)

Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies.
by: Yuka Otsuka, et al.
Published: (2018-08-01)

A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention
by: Young D. Kwon, et al.
Published: (2021-01-01)

Variable formation control of multiple robots via VRc and formation switching to accommodate large heading changes by leader robot
by: Sung-Gil Wee, et al.
Published: (2019-06-01)

Efficient regulatory approval of two novel HIV prevention interventions in a resource-limited setting: experiences from Zimbabwe
by: Caroline Murombedzi, et al.
Published: (2023-11-01)

Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor naïve human B cells
by: Jeong Hyun Lee, et al.
Published: (2021-09-01)

V5 region in the HIV-1 envelope glycoprotein determines viral sensitivity to the broadly neutralizing monoclonal antibody VRC01
by: Guo D, et al.
Published: (2012-09-01)

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
by: Kenneth H Mayer, et al.
Published: (2017-11-01)

Arrangement of VL and VH Domains in VRC01-Based Chimeric Antigen Receptor (CAR) Affects Functions and Exhaustion Status of CAR-T Cells
by: Jun-Ichi Nunoya, et al.
Published: (2021-01-01)

First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody
by: Denis R. Beckford-Vera, et al.
Published: (2022-03-01)